메뉴 건너뛰기




Volumn 6, Issue , 2013, Pages 107-118

Palliative systemic therapy for women with recurrent epithelial ovarian cancer: Current options

Author keywords

Biologic agents; Ovarian cancer; Systemic therapy

Indexed keywords

AFLIBERCEPT; ALTRETAMINE; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CEDIRANIB; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; EPOTHILONE B; ETOPOSIDE; GEMCITABINE; IMATINIB; IRINOTECAN; NAVELBINE; NINTEDANIB; PACLITAXEL; PAZOPANIB; PLACEBO; PLATINUM COMPLEX; SORAFENIB; SUNITINIB; TAXANE DERIVATIVE; TOPOTECAN; TRABECTEDIN; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR; VINTAFOLIDE;

EID: 84875036495     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: 10.2147/OTT.S30238     Document Type: Review
Times cited : (25)

References (76)
  • 1
    • 70450190156 scopus 로고    scopus 로고
    • Canadian Cancer Society's Steering Committee on Cancer Statistics, Toronto, ON: Canadian Cancer Society, Available from:, Accessed September 15, 2012
    • Canadian Cancer Society's Steering Committee on Cancer Statistics. Canadian Cancer Statistics 2012. Toronto, ON: Canadian Cancer Society; 2012. Available from: http://www.cancer.ca/Canada-wide/About%20cancer/~/media/CCS/Canada%20wide/Files%20List/English%20files%20heading/PDF%20-%20Policy%20-%20Canadian%20Cancer%20Statistics%20-%20English/Canadian%20Cancer%20Statistics%202012%20-%20English.ashx. Accessed September 15, 2012.
    • (2012) Canadian Cancer Statistics 2012
  • 2
    • 74549117921 scopus 로고    scopus 로고
    • Epithelial ovarian cancer
    • In: Barakat RR, Markman M, Randall ME, editors., Philadelphia: Wolters Kluwer Health, Lippincott Williams & Wilkins
    • Fleming GF, Ronnett BM, Seidman J, Zaino RJ, Rubin SC. Epithelial ovarian cancer. In: Barakat RR, Markman M, Randall ME, editors. Principles and Practice of Gynecologic Oncology. Philadelphia: Wolters Kluwer Health, Lippincott Williams & Wilkins; 2009:763-854.
    • (2009) Principles and Practice of Gynecologic Oncology , pp. 763-854
    • Fleming, G.F.1    Ronnett, B.M.2    Seidman, J.3    Zaino, R.J.4    Rubin, S.C.5
  • 3
    • 0141688377 scopus 로고    scopus 로고
    • Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study
    • Gynecology Oncology Group
    • Ozols RF, Bundy BN, Greer BE, et al; Gynecology Oncology Group. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003;21(17):3194-3200.
    • (2003) J Clin Oncol , vol.21 , Issue.17 , pp. 3194-3200
    • Ozols, R.F.1    Bundy, B.N.2    Greer, B.E.3
  • 4
    • 0026086870 scopus 로고
    • Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin
    • Markman M, Rothman R, Hakes T, et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol. 1991;9(3):389-393.
    • (1991) J Clin Oncol , vol.9 , Issue.3 , pp. 389-393
    • Markman, M.1    Rothman, R.2    Hakes, T.3
  • 5
    • 0030698757 scopus 로고    scopus 로고
    • Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: A multivariate analysis of 704 patients [see comments]
    • Eisenhauer EA, Vermorken JB, van Glabbeke M. Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients [see comments]. Ann Oncol. 1997;8(10):963-968.
    • (1997) Ann Oncol , vol.8 , Issue.10 , pp. 963-968
    • Eisenhauer, E.A.1    Vermorken, J.B.2    van Glabbeke, M.3
  • 6
    • 4143087249 scopus 로고    scopus 로고
    • Duration of response to second-line platinum-based chemotherapy for ovarian cancer: Implications for patient management and clinical trial design
    • Markman M, Markman J, Webster K, et al. Duration of response to second-line platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design. J Clin Oncol. 2004;22(15):3120-3125.
    • (2004) J Clin Oncol , vol.22 , Issue.15 , pp. 3120-3125
    • Markman, M.1    Markman, J.2    Webster, K.3
  • 7
    • 60749137451 scopus 로고    scopus 로고
    • Beyond chemotherapy: Targeted therapies in ovarian cancer
    • Yap TA, Carden CP, Kaye SB. Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer. 2009;9(3):167-181.
    • (2009) Nat Rev Cancer , vol.9 , Issue.3 , pp. 167-181
    • Yap, T.A.1    Carden, C.P.2    Kaye, S.B.3
  • 8
    • 39149118956 scopus 로고    scopus 로고
    • Optimal chemotherapy treatment for women with recurrent ovarian cancer
    • Fung-Kee-Fung M, Oliver T, Elit L, Oza A, Hirte HW, Bryson P. Optimal chemotherapy treatment for women with recurrent ovarian cancer. Curr Oncol. 2007;14(5):195-208.
    • (2007) Curr Oncol , vol.14 , Issue.5 , pp. 195-208
    • Fung-Kee-Fung, M.1    Oliver, T.2    Elit, L.3    Oza, A.4    Hirte, H.W.5    Bryson, P.6
  • 9
    • 0030900145 scopus 로고    scopus 로고
    • Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer
    • ten Bokkel Huinink W, Gore M, Carmichael J, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol. 1997;15(6):2183-2193.
    • (1997) J Clin Oncol , vol.15 , Issue.6 , pp. 2183-2193
    • ten Bokkel Huinink, W.1    Gore, M.2    Carmichael, J.3
  • 10
    • 0035879099 scopus 로고    scopus 로고
    • Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal doxorubicin versus topotecan
    • Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol. 2001;19(14):3312-3322.
    • (2001) J Clin Oncol , vol.19 , Issue.14 , pp. 3312-3322
    • Gordon, A.N.1    Fleagle, J.T.2    Guthrie, D.3    Parkin, D.E.4    Gore, M.E.5    Lacave, A.J.6
  • 11
    • 0037862963 scopus 로고    scopus 로고
    • Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: The ICON4/AGO-OVAR-2.2 trial
    • ICON and AGO Collaborators
    • Parmar MK, Ledermann JA, Colombo N, et al; ICON and AGO Collaborators. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet. 2003;361(9375):2099-2106.
    • (2003) Lancet , vol.361 , Issue.9375 , pp. 2099-2106
    • Parmar, M.K.1    Ledermann, J.A.2    Colombo, N.3
  • 12
    • 20044389455 scopus 로고    scopus 로고
    • Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: A GEICO (Grupo Espanol de Investigacion en Cancer de Ovario) study
    • González-Martín AJ, Calvo E, Bover I, et al. Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Espanol de Investigacion en Cancer de Ovario) study. Ann Oncol. 2005;16(5):749-755.
    • (2005) Ann Oncol , vol.16 , Issue.5 , pp. 749-755
    • González-Martín, A.J.1    Calvo, E.2    Bover, I.3
  • 13
    • 33750588670 scopus 로고    scopus 로고
    • Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: An intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG
    • AGO-OVAR; NCIC CTG; EORTC GCG
    • Pfisterer J, Plante M, Vergote I, et al; AGO-OVAR; NCIC CTG; EORTC GCG. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol. 2006;24(29):4699-4707.
    • (2006) J Clin Oncol , vol.24 , Issue.29 , pp. 4699-4707
    • Pfisterer, J.1    Plante, M.2    Vergote, I.3
  • 14
    • 0035056323 scopus 로고    scopus 로고
    • Carboplatin alone vs carboplatin plus epidoxorubicin as second-line therapy for cisplatin-or carboplatin-sensitive ovarian cancer
    • Associazione per Ricerca in Ginecologia Oncologia (ARGO 96) Study Group
    • Bolis G, Scarfone G, Giardina G, et al; Associazione per Ricerca in Ginecologia Oncologia (ARGO 96) Study Group. Carboplatin alone vs carboplatin plus epidoxorubicin as second-line therapy for cisplatin-or carboplatin-sensitive ovarian cancer. Gynecol Oncol. 2001;81(1):3-9.
    • (2001) Gynecol Oncol , vol.81 , Issue.1 , pp. 3-9
    • Bolis, G.1    Scarfone, G.2    Giardina, G.3
  • 15
    • 0036498921 scopus 로고    scopus 로고
    • Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens
    • Cantú MG, Buda A, Parma G, et al. Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens. J Clin Oncol. 2002;20(5):1232-1237.
    • (2002) J Clin Oncol , vol.20 , Issue.5 , pp. 1232-1237
    • Cantú, M.G.1    Buda, A.2    Parma, G.3
  • 16
    • 37349126263 scopus 로고    scopus 로고
    • Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwestern Oncology Group Protocol S02000)
    • Southwest Oncology Group
    • Alberts DS, Liu PY, Wilczynski SP, et al; Southwest Oncology Group. Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwestern Oncology Group Protocol S02000). Gynecol Oncol. 2008;108(1):90-94.
    • (2008) Gynecol Oncol , vol.108 , Issue.1 , pp. 90-94
    • Alberts, D.S.1    Liu, P.Y.2    Wilczynski, S.P.3
  • 17
    • 75749110481 scopus 로고    scopus 로고
    • Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: Final survival results of a SWOG (S0200) phase 3 randomized trial
    • Markman M, Moon J, Wilczynski S, et al. Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trial. Gynecol Oncol. 2010;116(3):323-325.
    • (2010) Gynecol Oncol , vol.116 , Issue.3 , pp. 323-325
    • Markman, M.1    Moon, J.2    Wilczynski, S.3
  • 18
    • 77955491837 scopus 로고    scopus 로고
    • Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer
    • Monk BJ, Herzog TJ, Kaye SB, et al. Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer. J Clin Oncol. 2010;28(19):3107-3114.
    • (2010) J Clin Oncol , vol.28 , Issue.19 , pp. 3107-3114
    • Monk, B.J.1    Herzog, T.J.2    Kaye, S.B.3
  • 19
    • 77954726606 scopus 로고    scopus 로고
    • Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse
    • Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, et al. Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol. 2010;28(20):3323-3329.
    • (2010) J Clin Oncol , vol.28 , Issue.20 , pp. 3323-3329
    • Pujade-Lauraine, E.1    Wagner, U.2    Aavall-Lundqvist, E.3
  • 20
    • 84875015659 scopus 로고    scopus 로고
    • Members of the Gynecologic Cancer Disease Site Group, Toronto, ON: Program in Evidence-based Care (PEBC), Cancer Care Ontario (CCO), Available from:, Accessed December 10, 2012
    • Fung Kee Fung M, Kennedy E, Francis J, Mackay H; members of the Gynecologic Cancer Disease Site Group. Optimal Chemotherapy for Recurrent Ovarian Cancer. Toronto, ON: Program in Evidence-based Care (PEBC), Cancer Care Ontario (CCO); 2011. Available from: https://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=34203. Accessed December 10, 2012.
    • (2011) Optimal Chemotherapy for Recurrent Ovarian Cancer
    • Fung Kee Fung, M.1    Kennedy, E.2    Francis, J.3    McKay, H.4
  • 21
    • 70349878651 scopus 로고    scopus 로고
    • Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: A phase 3, open-label, randomised controlled trial
    • Japanese Gynecologic Oncology Group
    • Katsumata N, Yasuda M, Takahashi F, et al; Japanese Gynecologic Oncology Group. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet. 2009;374(9698):1331-1338.
    • (2009) Lancet , vol.374 , Issue.9698 , pp. 1331-1338
    • Katsumata, N.1    Yasuda, M.2    Takahashi, F.3
  • 22
    • 84875017448 scopus 로고    scopus 로고
    • North Eastern Germany Society of Gynecologic Oncology, In, [website on the Internet]. Bethesda, MD:US National Library of Medicine; 2011 [updated August 26, 2011]. Available from:, NLM identifier: HECTOR. Accessed December 20, 2012
    • North Eastern Germany Society of Gynecologic Oncology. Hycamtin Plus carboplatinum versus established regimens for the treatment of ovarian cancer relapse. In ClinicalTrials. gov [website on the Internet]. Bethesda, MD:US National Library of Medicine; 2011 [updated August 26, 2011]. Available from: http://clinicaltrial.gov/ct2/show/NCT00437307?term=NCT00437307&rank=1. NLM identifier: HECTOR. Accessed December 20, 2012.
    • Hycamtin Plus carboplatinum versus established regimens for the treatment of ovarian cancer relapse
  • 23
    • 4644225190 scopus 로고    scopus 로고
    • Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer
    • Doxil Study 30-49 Investigators
    • Gordon AN, Tonda M, Sun S, Rackoff W; Doxil Study 30-49 Investigators. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol. 2004;95(1):1-8.
    • (2004) Gynecol Oncol , vol.95 , Issue.1 , pp. 1-8
    • Gordon, A.N.1    Tonda, M.2    Sun, S.3    Rackoff, W.4
  • 24
    • 0942287951 scopus 로고    scopus 로고
    • Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma
    • International Topotecan Study Group
    • ten Bokkel Huinink W, Lane SR, Ross GA; International Topotecan Study Group. Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma. Ann Oncol. 2004;15(1):100-103.
    • (2004) Ann Oncol , vol.15 , Issue.1 , pp. 100-103
    • ten Bokkel Huinink, W.1    Lane, S.R.2    Ross, G.A.3
  • 26
    • 0036137098 scopus 로고    scopus 로고
    • A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer
    • Gore M, Oza A, Rustin G, et al. A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer. Eur J Cancer. 2002;38(1):57-63.
    • (2002) Eur J Cancer , vol.38 , Issue.1 , pp. 57-63
    • Gore, M.1    Oza, A.2    Rustin, G.3
  • 27
    • 34447570846 scopus 로고    scopus 로고
    • Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer
    • Mutch DG, Orlando M, Goss T, et al. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2007;25(19):2811-2818.
    • (2007) J Clin Oncol , vol.25 , Issue.19 , pp. 2811-2818
    • Mutch, D.G.1    Orlando, M.2    Goss, T.3
  • 28
    • 0032903679 scopus 로고    scopus 로고
    • Paclitaxel vs epidoxorubicin plus paclitaxel as second-line therapy for platinum-refractory and-resistant ovarian cancer
    • Bolis G, Parazzini F, Scarfone G, et al. Paclitaxel vs epidoxorubicin plus paclitaxel as second-line therapy for platinum-refractory and-resistant ovarian cancer. Gynecol Oncol. 1999;72(1):60-64.
    • (1999) Gynecol Oncol , vol.72 , Issue.1 , pp. 60-64
    • Bolis, G.1    Parazzini, F.2    Scarfone, G.3
  • 29
    • 0000087270 scopus 로고    scopus 로고
    • Randomized trial comparing paclitaxel + doxorubincin (AT) versus paclitaxel (T) as second line therapy for advanced ovarian cancer (AOC) patients in early progression after platinum based chemotherapy [ASCO abstract 1506]
    • Torri V, Floriani I, Tinazzi A, et al. Randomized trial comparing paclitaxel + doxorubincin (AT) versus paclitaxel (T) as second line therapy for advanced ovarian cancer (AOC) patients in early progression after platinum based chemotherapy [ASCO abstract 1506]. Proceedings of the American Society of Clinical Oncology. 2000;19:381a.
    • (2000) Proceedings of the American Society of Clinical Oncology , vol.19
    • Torri, V.1    Floriani, I.2    Tinazzi, A.3
  • 30
    • 3042792377 scopus 로고    scopus 로고
    • Randomised controlled trial comparing single agent paclitaxel vs epidoxorubicin plus paclitaxel in patients with advanced ovarian cancer in early progression after platinum-based chemotherapy: An Italian Collaborative Study from the 'Mario Negri' Institute, Milan, GONO (Gruppo Oncologico Nord Ovest) group and IOR (Istituto Oncologico Romagnolo) group
    • Buda A, Floriani I, Rossi R, et al. Randomised controlled trial comparing single agent paclitaxel vs epidoxorubicin plus paclitaxel in patients with advanced ovarian cancer in early progression after platinum-based chemotherapy: an Italian Collaborative Study from the 'Mario Negri' Institute, Milan, GONO (Gruppo Oncologico Nord Ovest) group and IOR (Istituto Oncologico Romagnolo) group. Br J Cancer. 2004;90(11):2112-2117.
    • (2004) Br J Cancer , vol.90 , Issue.11 , pp. 2112-2117
    • Buda, A.1    Floriani, I.2    Rossi, R.3
  • 31
    • 49249130845 scopus 로고    scopus 로고
    • Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: Results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group
    • Sehouli J, Stengel D, Oskay-Oezcelik G, et al. Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. J Clin Oncol. 2008;26(19):3176-3182.
    • (2008) J Clin Oncol , vol.26 , Issue.19 , pp. 3176-3182
    • Sehouli, J.1    Stengel, D.2    Oskay-Oezcelik, G.3
  • 32
    • 84856331988 scopus 로고    scopus 로고
    • Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: The CARTAXHY randomized phase II trial from Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO)
    • GINECO group France
    • Lortholary A, Largillier R, Weber B, et al; GINECO group France. Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO). Ann Oncol. 2012;23(2):346-352.
    • (2012) Ann Oncol , vol.23 , Issue.2 , pp. 346-352
    • Lortholary, A.1    Largillier, R.2    Weber, B.3
  • 33
    • 20144377216 scopus 로고    scopus 로고
    • Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails
    • Sessa C, De Braud F, Perotti A, et al. Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. J Clin Oncol. 2005;23(9):1867-1874.
    • (2005) J Clin Oncol , vol.23 , Issue.9 , pp. 1867-1874
    • Sessa, C.1    de Braud, F.2    Perotti, A.3
  • 34
    • 33745245860 scopus 로고    scopus 로고
    • Phase I/II dose-escalation trial of patupilone every 3 weeks in patients with relapsed/refractory ovarian cancer [ASCO abstract 5056]
    • Smit WM, Šufliarsky J, Spanik S, et al. Phase I/II dose-escalation trial of patupilone every 3 weeks in patients with relapsed/refractory ovarian cancer [ASCO abstract 5056]. J Clin Oncol. 2005;23(16S):5056.
    • (2005) J Clin Oncol , vol.23 , Issue.16 S , pp. 5056
    • Smit, W.M.1    Šufliarsky, J.2    Spanik, S.3
  • 35
    • 84875014061 scopus 로고    scopus 로고
    • Results of a randomized, open-label, phase 3 trial of patupilone (P) versus pegylated liposomal doxorubicin (PLD) in taxane/platinum refractory/resistant patients with recurrent ovarian, fallopian or peritoneal cancer
    • [abstract 4843]; October 8-12, Milan, Italy
    • Colombo N, Schwartz PE, Bamias A. Results of a randomized, open-label, phase 3 trial of patupilone (P) versus pegylated liposomal doxorubicin (PLD) in taxane/platinum refractory/resistant patients with recurrent ovarian, fallopian or peritoneal cancer. Proceedings of the 35th European Society for Medical Oncology Congress [abstract 4843]; October 8-12, 2010; Milan, Italy.
    • (2010) Proceedings of the 35th European Society for Medical Oncology Congress
    • Colombo, N.1    Schwartz, P.E.2    Bamias, A.3
  • 36
    • 70350610540 scopus 로고    scopus 로고
    • Novel developments in angiogenesis cancer therapy
    • Hirte HW. Novel developments in angiogenesis cancer therapy. Curr Oncol. 2009;16(3):50-54.
    • (2009) Curr Oncol , vol.16 , Issue.3 , pp. 50-54
    • Hirte, H.W.1
  • 37
    • 36849019301 scopus 로고    scopus 로고
    • Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic Oncology Group Study
    • Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25(33):5165-5171.
    • (2007) J Clin Oncol , vol.25 , Issue.33 , pp. 5165-5171
    • Burger, R.A.1    Sill, M.W.2    Monk, B.J.3    Greer, B.E.4    Sorosky, J.I.5
  • 38
    • 37849035249 scopus 로고    scopus 로고
    • Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: A trial of the California, Chicago, and Princess Margaret Hospital phase II consortia
    • Garcia AA, Hirte H, Fleming G, et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol. 2008;26(1):76-82.
    • (2008) J Clin Oncol , vol.26 , Issue.1 , pp. 76-82
    • Garcia, A.A.1    Hirte, H.2    Fleming, G.3
  • 39
    • 36849056497 scopus 로고    scopus 로고
    • Phase II Study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer
    • Cannistra SA, Matulonis UA, Penson RT, et al. Phase II Study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol. 2007;25(33):5180-5186.
    • (2007) J Clin Oncol , vol.25 , Issue.33 , pp. 5180-5186
    • Cannistra, S.A.1    Matulonis, U.A.2    Penson, R.T.3
  • 40
    • 84866493383 scopus 로고    scopus 로고
    • AURELIA: A randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC) [ASCO abstract LBA5002]
    • Pujade-Lauraine E, Hilpert F, Weber B, et al. AURELIA: a randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC) [ASCO abstract LBA5002]. J Clin Oncol. 2012;30(S18):LBA5002.
    • (2012) J Clin Oncol , vol.30 , Issue.S18
    • Pujade-Lauraine, E.1    Hilpert, F.2    Weber, B.3
  • 41
    • 84861736119 scopus 로고    scopus 로고
    • OCEANS: A randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer
    • Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012;30(17):2039-2045.
    • (2012) J Clin Oncol , vol.30 , Issue.17 , pp. 2039-2045
    • Aghajanian, C.1    Blank, S.V.2    Goff, B.A.3
  • 42
    • 84869493683 scopus 로고    scopus 로고
    • Clinical trials and future potential of targeted therapy for ovarian cancer
    • Itamochi H, Kigawa J. Clinical trials and future potential of targeted therapy for ovarian cancer. Int J Clin Oncol. 2012;17(5):430-440.
    • (2012) Int J Clin Oncol , vol.17 , Issue.5 , pp. 430-440
    • Itamochi, H.1    Kigawa, J.2
  • 43
    • 36849005801 scopus 로고    scopus 로고
    • VEGF-trap for patients (pts) with recurrent platinum-resistant epithelial ovarian cancer (EOC): Preliminary results of a randomized, multicenter phase II study [ASCO abstract 5508]
    • Tew WP, Colombo N, Ray-Coquard I, et al. VEGF-trap for patients (pts) with recurrent platinum-resistant epithelial ovarian cancer (EOC): preliminary results of a randomized, multicenter phase II study [ASCO abstract 5508]. J Clin Oncol. 2007;25(S18):5508.
    • (2007) J Clin Oncol , vol.25 , Issue.S18 , pp. 5508
    • Tew, W.P.1    Colombo, N.2    Ray-Coquard, I.3
  • 44
    • 84856509199 scopus 로고    scopus 로고
    • Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: A phase 2, randomised, double-blind, placebo-controlled study
    • Gotlieb WH, Amant F, Advani S, et al. Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncol. 2012;13(2):154-162.
    • (2012) Lancet Oncol , vol.13 , Issue.2 , pp. 154-162
    • Gotlieb, W.H.1    Amant, F.2    Advani, S.3
  • 45
    • 58149219264 scopus 로고    scopus 로고
    • A phase II study of cediranib (AZD2171) in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: Final results of PMH, Chicago and California consortia Trial [ASCO abstract 5521]
    • Hirte HW, Vidal L, Fleming GF, et al. A phase II study of cediranib (AZD2171) in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: final results of PMH, Chicago and California consortia Trial [ASCO abstract 5521]. J Clin Oncol. 2008;26:5521.
    • (2008) J Clin Oncol , vol.26 , pp. 5521
    • Hirte, H.W.1    Vidal, L.2    Fleming, G.F.3
  • 46
    • 73949123481 scopus 로고    scopus 로고
    • Cediranib, an oral inhibitor of vascularendothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer
    • Matulonis UA, Berlin S, Ivy P, et al. Cediranib, an oral inhibitor of vascularendothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer J Clin Oncol. 2009;27(33):5601-5606.
    • (2009) J Clin Oncol , vol.27 , Issue.33 , pp. 5601-5606
    • Matulonis, U.A.1    Berlin, S.2    Ivy, P.3
  • 47
    • 84875028607 scopus 로고    scopus 로고
    • Boehringer Ingelheim Pharmaceuticals., In, [website on the Internet]. Bethesda, MD: US National Library of Medicine; [updated August 26, 2011]. Available from:, NLM identifier: NCT00710762. Accessed December 20, 2012
    • Boehringer Ingelheim Pharmaceuticals. A randomized placebo-controlled Phase 2study of continuous maintenance treatment with BIBF1120 following chemotherapy in patients with relapsed ovarian cancer. In ClinicalTrials. gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2011 [updated August 26, 2011]. Available from: http://clinicaltrial.gov/ct2/show/NCT00710762?term=NCT00710762& rank=1. NLM identifier: NCT00710762. Accessed December 20, 2012.
    • (2011) A randomized placebo-controlled Phase 2study of continuous maintenance treatment with BIBF1120 following chemotherapy in patients with relapsed ovarian cancer
  • 48
    • 80053561888 scopus 로고    scopus 로고
    • Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF1120 after chemotherapy for relapsed ovarian cancer
    • Ledermann JA, Hackshaw A, Kaye S, et al. Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF1120 after chemotherapy for relapsed ovarian cancer. J Clin Oncol. 2011;29(28):3798-3804.
    • (2011) J Clin Oncol , vol.29 , Issue.28 , pp. 3798-3804
    • Ledermann, J.A.1    Hackshaw, A.2    Kaye, S.3
  • 49
    • 58149225750 scopus 로고    scopus 로고
    • Phase II trial of sorafenib in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer; a Gynaecologic Oncology Group Study [ASCO abstract 5537]
    • Matei D, Sill MW, DeGeest K, Bristow RE. Phase II trial of sorafenib in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer; a Gynaecologic Oncology Group Study [ASCO abstract 5537]. J Clin Oncol. 2008;26:5537.
    • (2008) J Clin Oncol , vol.26 , pp. 5537
    • Matei, D.1    Sill, M.W.2    DeGeest, K.3    Bristow, R.E.4
  • 50
    • 49249113484 scopus 로고    scopus 로고
    • Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity
    • Azad NS, Posadas EM, Kwitkowski VE, et al. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol. 2008;26(22):3709-3714.
    • (2008) J Clin Oncol , vol.26 , Issue.22 , pp. 3709-3714
    • Azad, N.S.1    Posadas, E.M.2    Kwitkowski, V.E.3
  • 51
    • 45949109741 scopus 로고    scopus 로고
    • CA-125 response as a marker of clinical benefit in patients with recurrent ovarian cancer treated with gemcitabine and sorafenib: A trial of the PMH Phase II Consortium [ASCO abstract 5519]
    • Welch S, Hirte H, Elit L, et al. CA-125 response as a marker of clinical benefit in patients with recurrent ovarian cancer treated with gemcitabine and sorafenib: A trial of the PMH Phase II Consortium [ASCO abstract 5519]. J Clin Oncol. 2007;25(Suppl 18S):5519.
    • (2007) J Clin Oncol , vol.25 , Issue.SUPPL. 18 , pp. 5519
    • Welch, S.1    Hirte, H.2    Elit, L.3
  • 52
    • 81555203775 scopus 로고    scopus 로고
    • Charite University, Berlin, Germany., In, [website on the Internet]. Bethesda, MD: US National Library of Medicine; [updated August 26, 2011]. Available from:, NLM identifier: NCT 01047891. Accessed December 20, 2012
    • Charite University, Berlin, Germany. Efficacy and safety study of sorafenib with Topotecan in patients with platinum resistant recurrent ovarian cancer. In ClinicalTrials. gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2011 [updated August 26, 2011]. Available from: http://clinicaltrial.gov/ct2/show/NCT01047891?term=NCT01047891&rank=1. NLM identifier: NCT 01047891. Accessed December 20, 2012.
    • (2011) Efficacy and safety study of sorafenib with Topotecan in patients with platinum resistant recurrent ovarian cancer
  • 53
    • 84875046957 scopus 로고    scopus 로고
    • NCI., In, [website on the Internet]. Bethesda, MD: US National Library of Medicine; [updated August 26, 2011]. Available from:, Accessed December 20, 2012, NLM identifier: NCT 00096200
    • NCI. Sorafenib with or without paclitaxel and carboplatin in treating patients with recurrent ovarian cancer, primary peritoneal cancer or fallopian tube cancer. In ClinicalTrials. gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2011 [updated August 26, 2011]. Available from: http://clinicaltrials.gov/ct2/show/NCT00096200?term=NCT00096200&rank=1. NLM identifier: NCT 00096200. Accessed December 20, 2012.
    • (2011) Sorafenib with or without paclitaxel and carboplatin in treating patients with recurrent ovarian cancer, primary peritoneal cancer or fallopian tube cancer
  • 54
    • 79251585977 scopus 로고    scopus 로고
    • A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: An NCIC Clinical Trials Group Study
    • Biagi JJ, Oza AM, Chalchal HI, et al. A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study. Ann Oncol. 2011;22(2):335-340.
    • (2011) Ann Oncol , vol.22 , Issue.2 , pp. 335-340
    • Biagi, J.J.1    Oza, A.M.2    Chalchal, H.I.3
  • 55
    • 84865556743 scopus 로고    scopus 로고
    • A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: A randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy
    • Baumann KH, du Bois A, Meier W, et al. A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy. Ann Oncol. 2012;23(9):2265-2271.
    • (2012) Ann Oncol , vol.23 , Issue.9 , pp. 2265-2271
    • Baumann, K.H.1    du Bois, A.2    Meier, W.3
  • 56
    • 84875036357 scopus 로고    scopus 로고
    • A phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma
    • August 9, Pii: S0090-8258(12)00652-X
    • Campos SM, Penson RT, Matulonis U, et al. A phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma. Gynecol Oncol. August 9, 2012; Pii: S0090-8258(12)00652-X.
    • (2012) Gynecol Oncol
    • Campos, S.M.1    Penson, R.T.2    Matulonis, U.3
  • 57
    • 77956649079 scopus 로고    scopus 로고
    • A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer
    • Friedlander M, Hancock KC, Rischin D, et al. A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. Gynecol Oncol. 2010;119(1):32-37.
    • (2010) Gynecol Oncol , vol.119 , Issue.1 , pp. 32-37
    • Friedlander, M.1    Hancock, K.C.2    Rischin, D.3
  • 58
    • 84898448687 scopus 로고    scopus 로고
    • A phase II study of pazopanib in recurrent or persistent ovarian (EOC), peritoneal (PPC), or fallopian tube cancer (FTC): A Spanish Ovarian Cancer Group (GEICO) study [ASCO abstract 5068]
    • Oaknin A, Gonzalez-Martin A, García Y, et al. A phase II study of pazopanib in recurrent or persistent ovarian (EOC), peritoneal (PPC), or fallopian tube cancer (FTC): a Spanish Ovarian Cancer Group (GEICO) study [ASCO abstract 5068]. J Clin Oncol. 2012;30:5068.
    • (2012) J Clin Oncol , vol.30 , pp. 5068
    • Oaknin, A.1    Gonzalez-Martin, A.2    García, Y.3
  • 59
    • 83255192931 scopus 로고    scopus 로고
    • Activity of cabozantinib (XL184) in advanced ovarian cancer patients (pts): Results from a phase II randomized discontinuation trial (RDT) [ASCO abstract 5008]
    • Buckanovich RJ, Berger R, Sella A, et al. Activity of cabozantinib (XL184) in advanced ovarian cancer patients (pts): results from a phase II randomized discontinuation trial (RDT) [ASCO abstract 5008]. J Clin Oncol. 2011;29:5008.
    • (2011) J Clin Oncol , vol.29 , pp. 5008
    • Buckanovich, R.J.1    Berger, R.2    Sella, A.3
  • 60
    • 84863012011 scopus 로고    scopus 로고
    • Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer
    • Karlan BY, Oza AM, Richardson GE, et al. Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. J Clin Oncol. 2012;30(4):362-371.
    • (2012) J Clin Oncol , vol.30 , Issue.4 , pp. 362-371
    • Karlan, B.Y.1    Oza, A.M.2    Richardson, G.E.3
  • 62
    • 84875017972 scopus 로고    scopus 로고
    • AMGEN., Bethesda, MD: US National Library of Medicine; [updated August 26, 2011]. Available from:, NLM identifier: TRINOVA-2. Accessed December 20, 2012
    • AMGEN. TRINOVA-2. TRial IN OVArian cancer. Bethesda, MD: US National Library of Medicine; 2011 [updated August 26, 2011]. Available from: http://clinicaltrial.gov/ct2/show/NCT01281254?term=TRINOVA-2&rank=1. NLM identifier: TRINOVA-2. Accessed December 20, 2012.
    • (2011) TRINOVA-2. TRial IN OVArian cancer
  • 63
    • 77955649600 scopus 로고    scopus 로고
    • Targeting the epidermal growth factor receptor in epithelial ovarian cancer: Current knowledge and future challenges
    • Siwak DR, Carey M, Hennessy BT, et al. Targeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges. J Oncol. 2010;2010:568938.
    • (2010) J Oncol , pp. 568938
    • Siwak, D.R.1    Carey, M.2    Hennessy, B.T.3
  • 65
    • 79954431774 scopus 로고    scopus 로고
    • The therapeutic potential of targeting the EGFR family in epithelial ovarian cancer
    • Sheng Q, Liu J. The therapeutic potential of targeting the EGFR family in epithelial ovarian cancer. Br J Cancer. 2011;104(8):1241-1254.
    • (2011) Br J Cancer , vol.104 , Issue.8 , pp. 1241-1254
    • Sheng, Q.1    Liu, J.2
  • 66
    • 34547160422 scopus 로고    scopus 로고
    • A prospective analysis of imatinib-induced c-KIT modulation in ovarian cancer: A phase II clinical study with proteomic profiling
    • Posadas EM, Kwitkowski V, Kotz HL, et al. A prospective analysis of imatinib-induced c-KIT modulation in ovarian cancer: a phase II clinical study with proteomic profiling. Cancer. 2007;110(2):309-317.
    • (2007) Cancer , vol.110 , Issue.2 , pp. 309-317
    • Posadas, E.M.1    Kwitkowski, V.2    Kotz, H.L.3
  • 67
    • 84867500287 scopus 로고    scopus 로고
    • Role of farletuzumab in epithelial ovarian carcinoma
    • Jelovac D, Armstrong DK. Role of farletuzumab in epithelial ovarian carcinoma. Curr Pharm Des. 2012;18(25):3812-3815.
    • (2012) Curr Pharm Des , vol.18 , Issue.25 , pp. 3812-3815
    • Jelovac, D.1    Armstrong, D.K.2
  • 68
    • 84875018441 scopus 로고    scopus 로고
    • Morphotek., Bethesda, MD: US National Library of Medicine; [updated August 26, 2011]. Available from:, NLM identifier: FAR-122. Accessed December 20, 2012
    • Morphotek. An efficacy and safety study of MORAb-003in platinum-resistant or refractory relapsed ovarian cancer. Bethesda, MD: US National Library of Medicine; 2011 [updated August 26, 2011]. Available from: http://clinicaltrial.gov/ct2/show/NCT00738699?term=MORAB+in+platinum+resistent+ovarian+cancer&rank=1. NLM identifier: FAR-122. Accessed December 20, 2012.
    • (2011) An efficacy and safety study of MORAb-003in platinum-resistant or refractory relapsed ovarian cancer
  • 69
    • 77955887094 scopus 로고    scopus 로고
    • PRECEDENT: A randomized phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects with platinum-resistant ovarian cancer [ASCO abstract LBA5012b]
    • Naumann RW, Symanowski JT, Ghamande SA, et al. PRECEDENT: a randomized phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects with platinum-resistant ovarian cancer [ASCO abstract LBA5012b]. J Clin Oncol. 2010;28(S18):LBA5012b.
    • (2010) J Clin Oncol , vol.28 , Issue.S18
    • Naumann, R.W.1    Symanowski, J.T.2    Ghamande, S.A.3
  • 70
    • 84875015861 scopus 로고    scopus 로고
    • ENDOCYTE., Bethesda, MD: US National Library of Medicine; [updated August 26, 2011]. Available from:, NLM identifier: NCT01170650. Accessed December 20, 2012
    • ENDOCYTE. Study for women with platinum resistant ovarian cancer evaluating EC145in combination with Doxil®. Bethesda, MD: US National Library of Medicine; 2011 [updated August 26, 2011]. Available from: http://clinicaltrial.gov/ct2/show/NCT01170650?term=NCT01170650&rank=1. NLM identifier: NCT01170650. Accessed December 20, 2012.
    • (2011) Study for women with platinum resistant ovarian cancer evaluating EC145in combination with Doxil®
  • 72
    • 68149161777 scopus 로고    scopus 로고
    • Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA-deficient advanced ovarian cancer [ASCO abstract 5500]
    • Audeh MW, Penson RT, Friedlander M, et al. Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA-deficient advanced ovarian cancer [ASCO abstract 5500]. J Clin Oncol. 2009;27(S15):5500.
    • (2009) J Clin Oncol , vol.27 , Issue.S15 , pp. 5500
    • Audeh, M.W.1    Penson, R.T.2    Friedlander, M.3
  • 73
    • 84863010984 scopus 로고    scopus 로고
    • Phase II open label, randomized, multicentre study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor to pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2mutations and recurrent ovarian cancer
    • Kaye SB, Kaufman B, Lubinski J, et al. Phase II open label, randomized, multicentre study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor to pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2mutations and recurrent ovarian cancer. J Clin Oncol. 2012;30(4):372-379.
    • (2012) J Clin Oncol , vol.30 , Issue.4 , pp. 372-379
    • Kaye, S.B.1    Kaufman, B.2    Lubinski, J.3
  • 74
    • 80053135643 scopus 로고    scopus 로고
    • Phase II randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC) [ASCO abstract 5003]
    • Ledermann JA, Harter P, Gourley C, et al. Phase II randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC) [ASCO abstract 5003]. J Clin Oncol. 2011;29(S):5003.
    • (2011) J Clin Oncol , vol.29 , Issue.S , pp. 5003
    • Ledermann, J.A.1    Harter, P.2    Gourley, C.3
  • 75
    • 80052389761 scopus 로고    scopus 로고
    • Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: A phase 2multicentre, open-label, non-randomised study
    • Gelmon KA, Tischkowitz M, Mackay H, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2multicentre, open-label, non-randomised study. Lancet Oncol. 2011;12(9):852-861.
    • (2011) Lancet Oncol , vol.12 , Issue.9 , pp. 852-861
    • Gelmon, K.A.1    Tischkowitz, M.2    McKay, H.3
  • 76
    • 84875033532 scopus 로고    scopus 로고
    • Abbott., Bethesda, MD: US National Library of Medicine; [updated August 26, 2011]. Available from:, NLM identifier: NCT01170650. Accessed December 20, 2012
    • Abbott. A trial of ABT-888in combination with Temozolomide versus pegylated liposomal doxorubicin alone in ovarian cancer. Bethesda, MD: US National Library of Medicine; 2011 [updated August 26, 2011]. Available from: http://clinicaltrials.gov/ct2/show/NCT01113957?term=NCT01113957&rank=1. NLM identifier: NCT01170650. Accessed December 20, 2012.
    • (2011) A trial of ABT-888in combination with Temozolomide versus pegylated liposomal doxorubicin alone in ovarian cancer


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.